Elcys

Elcelyx Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for metabolic diseases by leveraging its proprietary Gut-Sensory Signaling (GSS) platform. The company's lead program, Metformin DR (delayed-release), is designed to deliver metformin specifically to the lower small intestine to maximize local gut-mediated effects while minimizing systemic absorption and associated side effects. This approach aims to provide a safer and more effective treatment option for patients with type 2 diabetes, particularly those with renal impairment who are currently contraindicated for standard metformin. Elcelyx is also exploring the broader application of its GSS platform to modulate the release of metabolic hormones like GLP-1 and PYY for the treatment of obesity and other metabolic disorders.